A cirrhosis/hepatology medication curriculum that separates encephalopathy treatment, portal-pressure control, HRS-AKI vasoconstriction and acute liver-failure antidotal therapy. It emphasizes precipitant/source control and avoids drug-only treatment of syndromes driven by bleeding, infection or hemodynamic failure.
Use lactulose clinically and avoid over-catharsis/electrolyte injury.
Know when rifaximin is adjunctive rather than first-line monotherapy.
Select terlipressin safely for HRS-AKI and recognize the 2026 respiratory-failure warning.
Start portal-pressure vasoactive therapy early in suspected variceal hemorrhage while arranging antibiotics/endoscopy.
Use N-acetylcysteine appropriately in acetaminophen toxicity and selected acute liver-failure contexts.
Integrated cirrhosis, HE, HRS, infection and bleeding management.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: First-line overt hepatic-encephalopathy pharmacotherapy.
Monitor: Mental status, stool number/consistency, Na/K, volume/renal function.
ICU role: Gut-directed add-on therapy for recurrent/persistent HE.
Monitor: HE recurrence, tolerance and adherence.
ICU role: Disease-specific vasopressin-agonist therapy for selected HRS-AKI.
Monitor: Continuous SpO2, volume status, SCr response, ischemia.
ICU role: Splanchnic vasoactive therapy for suspected acute variceal hemorrhage where used by local protocol.
Monitor: Bleeding trajectory, HR/glucose and endoscopic plan.
ICU role: Specific antidote for acetaminophen toxicity and selected ALF adjunctive therapy.
Monitor: AST/ALT, INR, acetaminophen level, acid-base/mental status.
ICU role: Common antibacterial prophylaxis/treatment component in acute variceal bleeding in advanced cirrhosis and for selected infections.
Monitor: Infection, allergy, biliary effects and culture data.
ICU role: Vitamin-K replacement when true deficiency or warfarin effect contributes to coagulopathy.
Monitor: Clinical bleeding, INR response only when deficiency/warfarin is relevant.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Lactulose Nonabsorbable Disaccharide / Ammonia-Lowering Laxative | First-line overt hepatic-encephalopathy pharmacotherapy. | ✓ Treat overt HE while correcting infection, GI bleeding, constipation, sedative/electrolyte precipitants. | ✕ Excessive diarrhea causes dehydration, hypernatremia and hypokalemia and can worsen HE/AKI. | Mental status, stool number/consistency, Na/K, volume/renal function. |
| Rifaximin Poorly Absorbed Rifamycin Antibacterial / Gut-Directed Ammonia-Lowering Therapy | Gut-directed add-on therapy for recurrent/persistent HE. | ✓ Add to lactulose for recurrent overt HE; useful for long-term recurrence reduction. | ✕ Does not replace precipitant treatment or acute lactulose-based therapy in most cases. | HE recurrence, tolerance and adherence. |
| Terlipressin Vasopressin Receptor Agonist / Splanchnic Vasoconstrictor | Disease-specific vasopressin-agonist therapy for selected HRS-AKI. | ✓ Use when HRS-AKI criteria/clinical context fit and oxygenation/ischemic risk allow. | ✕ Serious/fatal respiratory failure; do not initiate with hypoxia and avoid ongoing coronary/peripheral/mesenteric ischemia. | Continuous SpO2, volume status, SCr response, ischemia. |
| Octreotide Synthetic Somatostatin Analog / Splanchnic Vasoconstrictor | Splanchnic vasoactive therapy for suspected acute variceal hemorrhage where used by local protocol. | ✓ Start promptly in suspected portal hypertensive bleeding before definitive endoscopy. | ✕ Not definitive hemostasis and not routine therapy for nonvariceal upper-GI bleeding. | Bleeding trajectory, HR/glucose and endoscopic plan. |
| N-Acetylcysteine Glutathione precursor / antidote | Specific antidote for acetaminophen toxicity and selected ALF adjunctive therapy. | ✓ Start promptly when acetaminophen toxicity is suspected/indicated; delayed treatment can still be beneficial. | ✕ Do not use the acute nomogram for repeated supratherapeutic or uncertain chronic exposures. | AST/ALT, INR, acetaminophen level, acid-base/mental status. |
| Ceftriaxone 3rd-Generation Cephalosporin Antibiotic | Common antibacterial prophylaxis/treatment component in acute variceal bleeding in advanced cirrhosis and for selected infections. | ✓ Short-course antibacterial prophylaxis during acute variceal hemorrhage where guideline/local resistance profile supports it. | ✕ Not a substitute for diagnostic cultures/source control or a universal long-term prophylaxis drug. | Infection, allergy, biliary effects and culture data. |
| Vitamin K (IV) Essential Coagulation Cofactor / Hemostatic Vitamin | Vitamin-K replacement when true deficiency or warfarin effect contributes to coagulopathy. | ✓ Use when vitamin-K deficiency is plausible or documented rather than simply because INR is elevated in cirrhosis. | ✕ Cirrhotic INR elevation is not corrected meaningfully by vitamin K when deficiency is absent and does not directly measure bleeding risk. | Clinical bleeding, INR response only when deficiency/warfarin is relevant. |
Why: Over-catharsis can worsen kidney function and encephalopathy.
Why: Rifaximin is best established as adjunctive recurrence prevention; HE remains a clinical syndrome.
Why: Current U.S. labeling has a boxed respiratory-failure warning and contraindicates use during hypoxia/worsening respiratory symptoms.
Why: Early coordinated pharmacologic and endoscopic management reduces ongoing portal hypertensive bleeding risk.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
Cirrhotic patient is confused with asterixis after constipation and GI bleeding.
Treat the bleeding/constipation precipitant and give lactulose titrated to clinical response and about 2–3 soft stools/day.
Third HE admission despite appropriate lactulose use.
Add rifaximin 550 mg twice daily while continuing individualized lactulose and prevention of triggers.
Known cirrhosis presents with massive hematemesis and shock.
Resuscitate, start a portal-pressure vasoactive agent such as octreotide per local protocol plus antibacterial prophylaxis, and arrange urgent endoscopic hemostasis.
Cirrhosis, rising creatinine, no shock/nephrotoxin/structural kidney cause, SpO2 96%, no volume overload.
Use the current HRS-AKI pathway and consider terlipressin with careful albumin/volume strategy, monitoring SCr response and oxygenation continuously.
ACLF, SCr rising, MELD very high, new pulmonary edema and SpO2 89% after albumin challenge.
Do not force terlipressin into a hypoxic/high-risk phenotype. Treat respiratory/volume problems, reconsider albumin, coordinate transplant candidacy and renal-support strategy, and revisit HRS pharmacotherapy only if safety criteria improve.
First-line pharmacotherapy for overt hepatic encephalopathy in cirrhosis, titrated to clinical improvement and roughly 2–3 soft stools/day while avoiding dehydration, hypernatremia and hypokalemia from excessive diarrhea.
Poorly absorbed gut-directed rifamycin used mainly as add-on therapy to reduce recurrence of overt hepatic encephalopathy; it does not replace lactulose-based acute management or precipitant control in most ICU patients.
Vasopressin-receptor agonist approved in the U.S. to improve kidney function in adults with HRS and rapidly worsening kidney function. Benefit must be balanced against serious respiratory failure and ischemic risk, especially wit…
Long-acting synthetic octapeptide somatostatin analog that selectively induces splanchnic arteriolar vasoconstriction (via inhibition of vasodilatory glucagon and VIP), reducing portal venous inflow and variceal hemorrhage pressu…
Specific antidote for acetaminophen poisoning and an important therapy in selected non-acetaminophen acute liver failure contexts.
Workhorse 3rd-generation cephalosporin with strong Gram-negative and pneumococcal coverage, dual biliary/renal clearance, and high CNS penetration at 2g IV q12h for bacterial meningitis.
Parenteral fat-soluble vitamin essential for post-translational gamma-carboxylation of clotting factors II, VII, IX, and X in the liver, providing sustained endogenous factor regeneration during warfarin reversal and severe coagu…
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.